Targeted drugs have shown critical benefit to the treatment plans of other cancers, such as colorectal or breast cancer, such as Trastuzumab, a monoclonal antibody treatment for aggressive HER-2-positive breast cancer [52]. This evidence concerns the gene ERBB2 and breast carcinoma.